Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
196-210 of 298
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®Management of HER2-Low MBC Following First-Line Disease Progression
Peter Schmid, FRCP, MD, PhD
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Peter Schmid, FRCP, MD, PhD
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
MinuteCE®Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
Sara Lonardi, MD
Aparna R. Parikh, MD
Alan Venook, MD
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
Sara Lonardi, MD
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
MinuteCE®Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Alan Venook, MD
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
MinuteCE®Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Aparna R. Parikh, MD
- advertisement
William J. Gradishar, MD
Erica L. Mayer, MD, MPH
Peter Schmid, FRCP, MD, PhD
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
MinuteCE®The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
Peter Schmid, FRCP, MD, PhD
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
MinuteCE®Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Nicoletta Colombo, MD
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD
Wenxin Xu, MD
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
MinuteCE®Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
Ritu Salani, MD, MBA
Susana Campos, MD, MPH
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Wenxin Xu, MD
Sandy Srinivas, MD
- advertisement
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Wenxin Xu, MD
Sandy Srinivas, MD
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Wenxin Xu, MD
Sandy Srinivas, MD
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Ignacio Duran, MD
Sandy Srinivas, MD
